Tyra Biosciences Stock Surges on Phase 2 Trial Launch and Strong Cash Runway

Introduction

Tyra Biosciences Inc (NASDAQ: TYRA) is a clinical-stage biotechnology company headquartered in Carlsbad, California, focusing on precision medicines targeting fibroblast growth factor receptor (FGFR) biology. As of October 27, 2025, its shares traded at $14.69, reflecting an increase of 3.23% with a trading volume of 313,720 shares compared to a 50-day average of 81,466 shares, indicating a volume increase of approximately 285%. Tyra’s in-house SNÅP platform leverages structure-based design and co-crystal insights to develop small-molecule inhibitors in oncology and genetically defined conditions.

Corporate Structure

Founded in August 2018, Tyra employs between 11 and 50 people across research, clinical, regulatory, and administrative functions. Key leadership includes:

• Todd Harris (Co-founder & Chief Executive Officer), Ph.D. from MIT in Medical Engineering and Medical Physics
• Daniel Bensen (Co-founder & Chief Operating Officer), former Head of Immunology & Protein Chemistry at Cidara Therapeutics
• Ronald V. Swanson (Chief Scientific Officer), with 26 years of experience in biotech and pharma, Ph.D. from UC Berkeley in Molecular Biology
• Erik Goluboff, M.D. (SVP, Clinical Development), responsible for overseeing multiple FGFR-targeted trials

Biotechnology by Louis Reed

Recent Developments and News

On August 14, 2025, Tyra filed Form 10-Q for the quarter ended June 30, 2025, detailing its R&D investments and a projected cash runway extending into mid-2026. On the same day and subsequently on August 22, 2025, the company submitted Form 8-Ks to disclose leadership updates and other corporate matters.

In Q3 2025, dosing started in BEACH301, the Phase 2 study of dabogratinib (formerly TYRA-300) in children with achondroplasia. In August 2024, the FDA authorized an IND for TYRA-430, allowing a first-in-human Phase 1 trial for FGF19+/FGFR4-driven hepatocellular carcinoma. TYRA-200 is currently enrolling patients in SURF201, a multicenter Phase 1 study targeting FGFR2+ cholangiocarcinoma and other solid tumors.

On International Dwarfism Awareness Day (March 25, 2025), Tyra reiterated its commitment to the achondroplasia community. The company also supported the 2025 Bladder & Kidney Cancer Academy, where its Medical Director presented on advancements in addressing non-muscle invasive bladder cancer.

Financial and Strategic Analysis

Tyra’s August 14, 2025 10-Q indicates no product revenues to date, consistent with its clinical-stage status. R&D expenses increased year-over-year in alignment with trial advancements, while general and administrative costs remained under control. The company reported cash and cash equivalents adequate to support planned operations into the second half of 2026, assuming current burn rates are maintained.

Strategically, Tyra employs its SNÅP platform to produce molecular “SNÅPshots,” aimed at predicting resistance mutations and improving inhibitor selectivity. Its lead candidate, dabogratinib, targets FGFR3 with a focus on addressing gatekeeper resistance while minimizing FGFR1-related side effects. TYRA-430 and TYRA-200 expand the company’s portfolio to include FGFR4/3 and FGFR1/2/3 targets, respectively.

Market Position and Industry Context

The FGFR inhibitor market includes multiple approved and investigational agents. Tyra’s focus on FGFR3 selectivity targets unmet needs in non-muscle invasive bladder cancer, where FGFR3 mutations occur in up to 75% of cases, as well as in achondroplasia, which is primarily caused by FGFR3 mutations in over 99% of cases. The FGFR4/3 and FGFR1/2/3 programs aim to address specific needs in hepatocellular carcinoma and cholangiocarcinoma, where genetic alterations in FGFR2 are observed in approximately 15–20% of these cases. By integrating structural biology with advanced design methods, Tyra aims to differentiate its offerings and reduce off-target effects while addressing challenges related to acquired resistance.

TL;DR

• Shares at $14.69 on October 27, 2025 (+3.23%, volume spike)
• Q2 2025 10-Q (filed August 14) indicates increased R&D spend, cash runway into H2 2026
• Phase 2 dosing for dabogratinib in achondroplasia began in Q3 2025
• TYRA-430 Phase 1 IND cleared in August 2024; TYRA-200 currently enrolling in SURF201
• Upcoming milestones include Phase 2 data for BEACH301 and initial clinical readouts for TYRA-430 and TYRA-200